Vendor, Doylestown, PA
Merlin Biotech Inc.
UEI U33SZN8R3966, CAGE 9K6A1
1 award and -$55,000 obligated between August 20, 2026 and August 20, 2026, 100% under full and open competition, against 55.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | -$55,000 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00025Definitive Contract, September 16, 2025, Full and Open Competition After Exclusion of Sources, 55 offers | NIH NCINational Institutes of Health | SBIR FY25 Concept Award, Development of an Immunotherapy for Ewing Sarcoma Using a Novel Murine ModelNAICS 541715, PSC AN12 | $300,000 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 1 across 1 awards